Bio-Thera Solutions Expects First-Half 2026 Loss of 230-290 Million RMB on Higher R&D Costs
Bio-Thera Solutions expects a net loss of 230 million to 290 million RMB for the first half of 2026, widening from the prior period as research and development expenses rose by more than 100 million RMB. Sales of its adalimumab injection (Geloli) and tocilizumab injection (Shiruli) increased steadily year-on-year, but expense growth outpaced revenue growth, leading to the larger loss.
In the first half of 2026, sales of adalimumab injection (Geloli) and tocilizumab injection (Shiruli) increased steadily compared with the same period last year. The growth rate of expenses exceeded that of revenue, resulting in a larger net loss.